Defense Advanced Research Projects AgencyTagged Content List

Infectious Disease

Relating to ailments caused by pathogens

Showing 17 results for Disease + Countermeasures RSS
The Friend or Foe program aims to develop biosurveillance technology that can detect bacterial pathogens as, or even before, they threaten the military and homeland. The goal of the program is to quickly determine whether an unknown bacterium is harmless or virulent by directly identifying pathogenic behavior, avoiding conventional strategies that rely on known biomarkers.
The Pandemic Prevention Platform (P3) program aims to support military readiness and global stability through pursuit of novel methods to dramatically accelerate discovery, integration, pre-clinical testing, and manufacturing of medical countermeasures against infectious diseases. P3 confronts the reality that Department of Defense (DoD) personnel are not only deployed around the world for routine operations, but are often among the first responders to outbreaks of emerging or re-emerging disease with pandemic potential (e.g., Ebola). P3 aims specifically to develop a scalable, adaptable, rapid response platform capable of producing relevant numbers of doses against any known or previously unknown infectious threat within 60 days of identification of such a threat in order to keep the outbreak from escalating and decrease disruptions to the military and homeland.
The Pathogen Predators program focuses on force readiness and homeland protection through development of novel countermeasures against biological threats involving bacterial agents. Currently, the most common defense against such a threat is traditional antibiotics, but while such antibiotics have been remarkably effective in the past, their widespread use has heightened the risk of our troops contracting antibiotic-resistant bacterial infections that are difficult or impossible to treat. A new type of countermeasure is needed to overcome the threat posed by antibiotic-resistant bacteria.
Pathogens with pandemic potential, toxic chemicals, and radioactive materials all endanger public health and pose a threat to national security. Despite investment in the development of medical countermeasures (MCMs) to address these threats, many existing MCMs suffer from limited applicability, insufficient efficacy, requirements for repeat dosing, lengthy and complex manufacturing processes, and logistically burdensome storage requirements. In many cases, unique threats require unique responses, setting up a “one threat, one MCM” paradigm.
The Rapid Threat Assessment (RTA) program aims to provide critical information to speed production of medical countermeasures to protect U.S. forces against novel chemical and biological weapons. Such weapons have historically been mass-produced within a year of discovery. Development of countermeasures, however, currently takes far longer. Using current methods and technologies, researchers require decades of study to gain a cellular-level understanding of how new threat agents exert their effects.